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Abstract: The successful isolation of a human influenza virus in 1933 was soon followed 
by the first attempts to develop an influenza vaccine. Nowadays, vaccination is still the most 
effective method to prevent human influenza disease. However, licensed influenza vaccines 
offer protection against antigenically matching viruses, and the composition of these vaccines 
needs to be updated nearly every year. Vaccines that target conserved epitopes of influenza 
viruses would in principle not require such updating and would probably have a considerable 
positive impact on global human health in case of a pandemic outbreak. The extracellular 
domain of Matrix 2 (M2e) protein is an evolutionarily conserved region in influenza A 
viruses and a promising epitope for designing a universal influenza vaccine. Here we review 
the seminal and recent studies that focused on M2e as a vaccine antigen. We address the 
mechanism of action and the clinical development of M2e-vaccines. Finally, we try to 
foresee how M2e-based vaccines could be implemented clinically in the future. 
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1. Introduction 
Human influenza viruses are respiratory pathogens that are easily transmitted from an infected patient 
to another susceptible individual. The virus transmits by respiratory droplets and by contact. Seasonal 
flu epidemics cause an estimated 250,000 deaths worldwide each year [1]. Seasonal influenza can be 
fatal in the elderly and in patients with pulmonary or cardiovascular diseases [2]. Translated into absolute 
number of cases, the global burden of human influenza infection is huge. For example, it was estimated 
that in 2008 seasonal influenza viruses caused 90 million new infections worldwide in children below 5 
years of age and were responsible for up to 20% of all pediatric acute lower respiratory infections [3]. 
The catastrophic influenza pandemic that emerged in 1917–1918 and caused the so-called Spanish flu, 
killed an estimated 50 million people [4–6]. Ninety years later the world faced another H1N1 pandemic, 
commonly named the “Mexican flu”, which was caused by the 2009 H1N1 pandemic virus. This virus 
turned out to be much milder than its ancestor that emerged at the end of the First World War. Still it 
was estimated that it killed more than 200,000 people during the first 12 months of its circulation [7]. 
Influenza epidemics also cause considerable economic burden due to absence from work and school and 
increased hospitalization rates. In addition, the fear of zoonotic infections with avian influenza viruses 
and recurrent outbreaks of highly pathogenic influenza in poultry farms, killing vast numbers of animals 
in a very short time, comes with a huge cost for society. Furthermore, transmission of an H7N9 virus 
(classified as a low pathogenic influenza virus) from poultry to human, which started to surface in 
February 2013, was followed by closure of poultry markets and by now (fall of 2014) has caused direct 
and indirect economic losses of more than 1.8 billion US dollars [8]. 
Influenza viruses are negative-stranded RNA viruses belonging to the Orthomyxoviridae family, and 
have a segmented genome. Influenza A, B, and C type influenza viruses can be distinguished based on 
antigenic differences in the internal viral proteins. Only influenza A viruses are known to cause 
pandemics. Apart from humans, other natural hosts of influenza A viruses are pigs, horses, dogs, and 
waterfowl. This implies that there is a tremendous reservoir of influenza genes in those species. Since 
influenza viruses can exchange gene segments by a process called reassortment (antigenic shift), there 
is a constant awareness that such an unpredictable event could cause the next pandemic [9]. Influenza A 
viruses can be subtyped on the basis of genetic and antigenic differences in the two major membrane 
glycoproteins: hemagglutinin (HA) and neuraminidase (NA). There are 18 HA subtypes and 11 NA 
subtypes [10]. The pathogenicity and virulence of influenza A viruses are variable. For example the 
highly pathogenic avian influenza are mainly H5 and H7 viruses, and human H3N2 viruses are typically 
more virulent than H1N1 viruses. Factors that contribute to the pathogenicity of influenza A include the 
level of pre-existing immunity to the virus, the receptor specificity of the viral HA, the type of proteases 
that enable proteolytic maturation of HA and the genetic predisposition of the host [11–13]. Influenza B 
viruses are nearly exclusively found in humans, and infection with influenza C viruses are usually 
asymptomatic or cause mild upper respiratory tract infection [14–16]. 
Influenza is a preventable disease and vaccination is considered the most effective way to control the 
spread of disease caused by influenza viruses. Licensed influenza vaccines are based on eliciting 
neutralizing antibodies against HA and can be grouped into three types. First and most used are injectable 
influenza subunit vaccines like Fluarix® (GlaxoSmithKline, London, United Kingdom), Flulaval® 
(GlaxoSmithKline), Fluzone® (Sanofi Pasteur, Lyon, France), Afluria® (bioCSL Pty. Ltd., Pennsylvania, 
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PA, USA), Anflu® (Sinovac Biotech Ltd., Beijing, China), Fluvirin® (Novartis, Basel, Switzerland), 
Fluad® (Novartis), Begripal® (Novartis), cell-based Optaflu® (Novartis), and Flucelvax® (Novartis). A 
second type of vaccine is based on recombinant HA expression in insect cells, which is marketed as 
Flubloc® in the USA. The third vaccine is intranasally applied and consists of live-attenuated influenza 
viruses [17,18]. Surveillance studies over the past 15 years have revealed that next to the circulating 
A/H1N1 and A/H3N2 viruses, two antigenically distinct B virus types circulate: the so called B/Yamagata 
and B/Victoria lineages [19,20]. One of these two B lineage viruses tends to be dominant over the other 
during seasonal influenza. In hindsight, the vaccine composition was mismatched with regard to the 
prevalent influenza B virus in half of the flu seasons between 1999 and 2012 [21]. Therefore, 
quadrivalent vaccines with two A strains and two B strains are now marketed in several countries. 
Clinical studies indicate that these quadrivalent influenza vaccines are as safe as trivalent vaccines and 
are expected to provide broader protection against influenza B virus infection [22,23]. 
The adaptive immune response that is built up in the human population due to infection with seasonal 
influenza viruses creates an immune selection pressure on the circulating viruses, which favors fit mutant 
viruses that at least partially escape the prevailing herd immunity. Those escape viruses carry mutations 
in the major antigenic regions of HA and NA, and this subtle immune escape mechanism is known as 
antigenic drift. Because of this, the composition of human influenza vaccines is changed almost yearly 
to try to match the newly circulating drift viruses. The decision on the influenza vaccine composition is 
taken by specialists from the World Health Organization (WHO)’s Influenza Collaborating Centers, 
based on virological surveillance. This decision is made approximately six months before the anticipated 
start of the influenza season in moderate climate zones. Although the accuracy of the prediction has 
improved over the past decade, mismatches still occur, making the vaccines less effective. Clearly, in 
case of 2009 influenza pandemic outbreak, this prediction approach did not work and the Mexican flu 
outbreak in 2009 took the influenza experts by surprise. Even though since the 1970s there is an H1N1 
strain subtype present in human influenza vaccines, the HA from the pandemic A/California/04/2009 
was antigenically only remotely related to the HA subtypes from all human seasonal H1N1 strains that 
circulated between 1977 and 2008. Instead, the HA of A/California/04/2009 was antigenically more 
reminiscent of the early descendants of the 1918 pandemic virus. So, not surprisingly, the conventional 
influenza vaccines that were ready to go in production in the spring of 2009, would have been close to 
futile to control the 2009 pandemic H1N1 outbreak [24]. Such a profound antigenic change in HA 
(sometimes accompanied by a major change in NA subtype as well) compared with HA in previously 
circulating seasonal influenza viruses, is named an antigenic shift. 
As the epidemics of influenza A virus continue and the possible transmission of highly lethal avian 
influenza viruses from poultry to human remain a looming threat, vaccines that can induce broadly 
protective immune responses against influenza A are urgently needed. Approaches to achieve this are 
based on the induction of cross-reactive antibodies or T cell responses against the more conserved 
internal viral proteins. The aims are often to induce protection against all influenza A virus subtypes or 
in some cases against all virus strains from one subtype [25]. Here we focus on the development of 
universal influenza A vaccine candidates based on the conserved M2e. Its sequence conservation, 
accessibility for antibodies and the relative ease with which anti-M2e immunogenicity can be elicited 
have led to numerous attempts and designs of M2e-based universal influenza A vaccines, a few of which 
have even been evaluated in early stage clinical trials.  
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2. Biological Function of M2 
The influenza A virus genome codes for 11 polypeptides and a number of minor proteins that are 
expressed by most viral strains [26]. Lamb et al. discovered M2 in influenza A viruses and showed that 
it was encoded by gene segment 7. M2 contains 97 amino acids and is expressed from a spliced mRNA 
derived from the M1 mRNA [27]. M1 and M2 share the first nine amino acids at their NH2-termini [28]. 
The principle function of M2 is to act as a viroporin. Soon after virion entry in the host cell, M2 becomes 
activated by the acidic environment within the endosomes and as a result M2 conducts the flux of H+ 
ions across the viral membrane into the virion interior. This proton influx loosens the interactions 
between the viral ribonucleoprotein complexes (vRNPs) and M1, a process that is named “priming”. M2 
also allows the influx of potassium ions (K+) and sodium ions (Na+) although its permeability for K+ is 
105 to 106 fold lower than for protons [29]. However, the concentration of K+ in late endosomes is close 
to 100 mM, sufficiently high for M2 to let this cation pass. The influx of K+ into the virion interior causes 
a second priming event during which the conformation of M1 is changed further and the viral 
ribonucleoprotein complexes become relaxed [30]. The low endosomal pH also triggers the membrane 
fusion activity of HA, which catalyzes the fusion of the viral envelope with the endosomal membrane. 
Since by that time the electrostatic interaction between M1 and vRNPs are lost, membrane fusion is 
accompanied by the release of the vRNPs into the cytosol [31].  
M2 is a tetrameric type III membrane protein. Cysteine residues at position 17 and 19 are highly 
conserved and oxidized, and they presumably stabilize the tetrameric structure. The M2 protein can be 
divided into three parts: the extracellular N-terminal domain (M2e, positions 2–24), the transmembrane 
(TM) domain (positions 25–46) and the intracellular C-terminal domain (positions 47–97). 
The high sequence conservation of M2e among all known human influenza A viruses that circulated 
between 1918 and 2008, was key to its development as a universal human influenza A vaccine candidate 
(Figure 1A) [32]. A human influenza M2e consensus sequence was deduced, and this suggested that a 
human type M2 or M2e was somehow a prerequisite for influenza A viruses to be fit in the human host. 
However, the swine-origin H1N1 2009 pandemic virus proved this assumption wrong. This virus has 
avian origin gene segments 6 (encoding NA) and 7 (encoding M1/M2) and hence an “avian” type M2e, 
which differs at 4 positions from M2e of previously circulating human H1N1, H2N2, and H3N2 viruses 
(Figure 1B) [33]. The genetic relation between M2e and M1 explains the low variability in M2e. Amino 
acid residues 1–9 of M2e and M1 are encoded by the same nucleotides in the same reading frame. Amino 
acid residues 10–23 of M2e and 239–252 of M1 are also encoded by the same RNA sequence but are 
translated by different reading frames. A closer look at M2e shows that its N-terminal 9 amino acids are 
almost absolutely conserved, even in H17N10 and H18N11 influenza viruses that were recently isolated 
from bats (Figure 1B). M2e residues 10 to 24 are more variable. Still, in this region, Arg12, Trp15, 
Cys17, Cys19, and Ser22 are strongly conserved suggesting that these residues in M2e are functionally 
important. It is important to note that the sequence variation in the membrane proximal part of M2e is 
not comparable to the amino acid changes that contribute to antigenic drift in HA and NA. In the latter 
case, nearly any amino acid change is tolerated, whereas in the case of M2e, selection pressure is also 
imposed by the overlapping M1 codon sequence. An additional element that helps explain the relatively 
strong sequence conservation of M2e is the fact that M2e-specific antibody responses are hardly induced 
following an infection. Hence, there is probably only a low natural immune pressure directed against 
M2e [34]. 
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Figure 1. Mutation frequency of amino acids in human, avian, and swine consensus M2e. 
(A) Percentages of the residues which are different from consensus sequences were calculated 
based on 14,588 human, 9324 avian, and 3060 swine M2 sequences deposited in the National 
Center for Biotechnology Information (NCBI) databank; (B) Sequence alignments of M2e 
derived from different influenza A viruses. 
Apart from M1 and M2, there are two additional mRNAs transcribed from gene segment 7: mRNA3 
and −4. mRNA4 is produced by a splicing event that utilizes a suboptimal splice donor site, located in 
the beginning of the M1/M2 open reading frame, and the same splice acceptor site near the 3 end of the 
M1/M2 open reading frame. mRNA4 may give rise to an M2-like protein, named M42. M42 can 
functionally replace M2 in vitro and in vivo but it is non-essential for influenza A virus replication as 
long as M2 is adequately expressed [35]. In nature, M42 expression is probably restricted to a minority 
of influenza A virus strains, including human isolates and certain highly pathogenic avian influenza A 
virus strains [35]. Of note, the ectodomain of M42 is antigenically very different from M2. Experimental 
M2e-selection pressure might select for influenza A virus escape mutants that express M42, at the 
expense of M2. 
The TM four-helix bundle drives the tetramerization and forms the pore of the low-external-pH-sensitive 
ion channel. Several nuclear magnetic resonance (NMR) and X-ray crystal structures of the M2 TM and 
of parts of the intracellular domain of M2 have been resolved. The structure at pH7.5 reveals that residues 
18–23, corresponding to the extracellular membrane proximal part of M2e, and residues 47–50 are 
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unstructured. The channel-forming TM domain (residues 25–46) forms a helix bundle with a left-handed 
twist angle of ~23°. Residues 51–59 form an amphipathic helix, which, in the tetramer, is oriented almost 
perpendicularly (~82°) to the transmembrane helices. Molecular dynamics calculation based on the 
crystal structure (PDB id: 3BKD) [36] suggests that the tetrameric TM domain acts as a proton 
transporter with Val27 and His37 functioning as a gate [37]. Sharma et al. proposed a mechanism for 
the selective proton channel function of M2. In their model, His37 and Trp41 face the inside of the 
tetrameric TM channel and guide protons by forming and breaking hydrogen bonds between adjacent 
pairs of histidines and through interactions of the histidines with the tryptophan gate [38]. 
Amantadine and rimantadine are adamantane-like small molecule that can block the M2 proton 
channel and that have been used as an antiviral drugs. There are two binding sites for amantadine that 
explain M2 inhibition. One is a lipid-facing pocket around Asp44 by which the drug inhibits M2 function 
allosterically [39,40]. The other, probably more likely an amantadine/rimantadine-binding site, is inside 
the pore around Ser31 by which the drug acts as a plug that blocks the M2 pore [36,41]. 
The M2 cytosolic tail contributes to the stable tetramer formation. This part of M2 also participates 
in genome packaging and facilitates virus production [42]. Deletion of the M2 cytoplasmic tail results 
in reduced incorporation of vRNPs into virions and strongly attenuates the influenza A virus potency. 
The part of M2 encompassing residues 45 to 69 in the cytosolic tail interacts with M1 protein. It has also 
been shown that the C-terminal 28 residues of M2 are implicated in virion budding and filamentous 
influenza particle assembly and release [43,44]. In particular the amphipathic alpha helix in the cytosolic 
domain of M2 that is close to the membrane is highly conserved and is essential for virus assembly. 
Recently, Rossman et al. showed that this amphipathic helix mediated membrane scission by altering 
the membrane curvature in a cholesterol-dependent manner [45]. Mutation of hydrophobic residues in 
this alpha helix interfere with scission and virion release. The current model for influenza A virus 
budding proposes that HA mediates initiation of virus budding by assembling into lipid rafts. M2 is 
subsequently recruited to the boundary of these lipid rafts and causes membrane scission and release of 
virus [45]. This procedure is the ESCRT (host endosomal sorting complex)-independent making the 
process of membrane scission, the final step in the budding, in case of influenza virus unique and 
different from that of HIV-1, Ebola virus, and paramyxovirus PIV-5.  
The luminal side of the Golgi vesicles is relatively acidic. HA from most highly pathogenic H5 and 
H7 influenza viruses have a polybasic proteolytic maturation site that separates HA1 from HA2. As a 
result, the HA0 precursor from these viruses can be processed in the Golgi apparatus by furin-like 
proteases. Combined with the acidic environment in the Golgi vesicles, this means that HA could already 
convert to the post fusion state while in transit to the cell surface. M2, however, is also expressed in the 
Golgi and by its proton transport function, renders the Golgi less acidic. This prevents untimely 
conversion of HA from highly pathogenic influenza viruses into its fusogenic form [46]. The M2 proteins 
of different viruses vary in their ability to alter the trans-Golgi pH and the proton gating activity of M2 
seems to have co-evolved with the differences in the pH that triggers membrane fusion of HA in these 
viruses [47,48]. 
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M2 also influences innate host immune responses. The ion channel activity of M2 can trigger  
pro-inflammatory host responses by activating NLRP 3 inflammasomes in influenza A virus infected 
cells [49]. This activation requires M2 ion channel activity at the Golgi apparatus and operates in 
macrophages and dendritic cells. Autophagosome formation is an intrinsic part of eukaryotic cellular 
metabolism: it recycles cellular components and is implicated in the defense against intracellular 
pathogens. This process involves the transient formation of vesicles, called autophagosomes, that deliver 
cellular content such as proteins and worn-out organelles to the lysosomal compartment for degradation. 
Autophagy can act as an innate antiviral defense mechanism. For example herpes simplex virus-1, 
Kaposi’s sarcoma-associated herpesvirus and mouse herpesvirus 68, evolved to express proteins that can 
block the induction of autophagy, the maturation or degradation of autophagosomes [50]. Interestingly, 
autophagosomes accumulate after influenza A virus infection of human lung epithelial cells, but the 
degradation of these autophagosomes, which depends on their fusion with lysosomes, is hindered. M2 
is responsible for this inhibition, independent of the ion channel activity [51]. Recently, it was found 
that the highly conserved M2 LC3-interacting region (LIR) close to the C-terminus of M2 bound to 
the LC3/ATG8 family members residing on autophagosome membrane, which mediated the redistribution 
of autophagosome on the plasma membrane of influenza A virus infected cells. This interaction also 
recruits LC3 to the plasma membrane where virion budding occurs and might mobilize lipid resources for 
virion budding. Mutation of M2 residues in the LIR motif dramatically reduce virus production [51,52]. 
Possibly, this highly conserved and functional motif in the M2 cytoplasmic tail provides a new target to 
develop vaccines or antivirals. However, this motif is not exposed at the cell or virion exterior. 
3. M2-Specific Immune Responses Following Infection 
M2 is a structural protein that is also abundantly expressed on the surface of infected cells. So clearly, 
it is exposed to the adaptive immune system of the host. Nevertheless, influenza A virus infection of 
humans induces a weak anti-M2 antibody response that is of short duration [34,53]. A possible 
explanation for this low reactivity is the small size of M2e and its low abundance of M2 in virions 
compared to the large glycoproteins, HA, and NA [54]. Primary infection of pigs with a high dose of 
H1N1 virus induced very weak anti-M2e serum IgG response. However, reinfection of such pigs with 
an H3N2 virus six weeks after the primary infection increased the anti-M2e IgG response by more than 
10-fold [55]. A similar finding was reported in inbred and outbred mice. When mice were first infected 
with PR8 virus, then with PR8-Seq14 (a PR8-derived strain that evades HA-based neutralization) and 
thirdly with X31 virus (a H3N2 subtype virus), all animals displayed anti-M2e seroconversion. This 
experiment indicates that the B cell repertoire in these strains was able to generate anti-M2e antibodies [56]. 
From these experiments, one can conclude that M2e-specific antibody responses are poorly induced in 
the unprimed mammalian host, but that primary infection nevertheless elicits a degree of B cell immune 
memory against M2e that can be boosted by a subsequent heterosubtypic viral challenge. Experimental 
infection of chickens with avian influenza viruses results in a modest but detectable anti-M2e specific 
serum antibodies. This finding has practical implication and has been used to develop an assay to 
discriminate between infected and vaccinated chickens (DIVA) [57,58]. Ducks, for example, that were 
inoculated with inactivated avian influenza vaccine developed robust hemagglutination inhibition (HAI) 
titers but undetectable M2e specific antibodies [58].  
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Many people are frequently re-infected with influenza viruses. Zhong et al. analyzed the  
M2e-specific seroconversion during natural 2009 pandemic H1N1 infection in 118 individuals, ranging 
from 6 months to 53 years of age [59]. They found that the seroprevalence of anti-M2 antibodies 
increased with age and that a boost of this pre-existing humoral immunity against M2 was apparent 
following infection with pandemic H1N1 virus. In contrast, in people who had no anti-M2 antibodies 
before infection with the pandemic H1N1 virus, anti-M2 responses remained low in convalescent serum. 
The induced anti-M2 response also showed cross-reactivity with M2 from seasonal influenza A viruses [59]. 
It is unclear if these M2-specific antibodies contributed to protection against infection with the 2009 
pandemic virus. It is also important to note that these authors used a very sensitive ELISA method that 
is based on reactivity of IgG against M2 expressed on mammalian cells. Under these conditions, M2 is 
presented as a tetramer, and hence reactivity against quaternary epitopes in M2(e) were also detectable. 
To summarize, following natural or experimental infection with influenza A viruses, M2e-specific antibody 
responses in circulation remain low. Therefore, pre-existing anti-M2e immune responses are unlikely to 
interfere with M2e-based vaccines. 
4. T Cell Epitopes in M2e 
M2-specific T cell responses have been described in humans [60,61]. The human CD4 and CD8 CTL 
epitopes directed against M2 that have been defined experimentally and are shown in Figure 2 [60,62,63]. 
We reported the presence of an major histocompatibility complex (MHC) class II restricted T cell 
epitope in M2e, that is restricted to BALB/c mouse strains (H-2d) and was strongly induced by mucosal 
vaccination by means of the recombinant protein CTA1-M2e-DD [64]. The CD4 T cell epitopes in M2e 
have been mapped for the mouse. Pejoski et al. found that M2e2-16 (SLLTEVETPIRNEWG) peptide 
contains only B cell epitopes but no T cell epitope, which explains why immunization with M2e2-16 
peptide formulated in Freund’s adjuvant failed to induce antibody responses against M2e as present on 
virus particles. However, by including a chemically conjugated T helper epitope derived from HA in the 
M2e conjugate, M2e specific antibodies were readily generated [65]. In line with this, we reported that 
immunization with the N-terminal nine amino acids residue of M2e (SLLTEVETP) coupled to keyhole 
limpet haemocyanin (KLH) induced very low M2e-specific IgG responses [66]. 
 
Figure 2. M2 from PR8 virus with the identified human T cell epitopes underlined. 
M2e specific T cell responses varied with different host gene background. To test whether M2 
vaccines showed efficacy in mouse strains other than BALB/c mice (H-2d), Wolf et al. elucidated that 
immunization with truncated M2e2-16 adjuvanted with CpG 1826 and Cholera Toxin was able to elicit 
a significant anti-M2e antibody response that was associated with enhanced viral clearance after X31 
challenge in BALB/c (H-2d), but not in C57BL/6 (H-2b), C3H (H-2k), CD1/ICR, and Swiss Webster 
mouse strains [56]. The poor antibody responses in the latter mouse strains correlated with a lack of 
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M2e-specific T cell responses in these mice [56]. The group of Dr. Epstein compared M2-specific 
antibody and T cell responses in BALB/c (H-2d), CBA (H-2k) and C57BL/6 (H-2b) mice after 
vaccination with an M2 DNA expression vector to prime the animals followed by boosting with an 
Adenovirus expressing M2 [67]. They reported that BALB/c mice responded strongly, CBA mice and 
C57BL/6 intermediately to M2 and concluded that both the MHC and background genes controled the 
adaptive immune response to M2. However, immunization with ASO4 adjuvanted tandem M2e-displaying 
lipid enveloped virus like particles (VLP), reportedly induced M2e-specific CD4 T cell responses in 
C57BL/6 mice as determined by ELISPOT following in vitro restimulation with M2e peptide [68]. 
Interestingly, M2-responses could be increased by adjuvanted peptide-carrier antigens in otherwise 
poorly responding mouse strains. 
5. M2e-Based Vaccines 
M2e has low immunogenicity in nature and is often fused with a larger carrier to enhance anti-M2e 
immune responses in vaccination experiments. M2e has been coupled to a plethora of carriers, usually 
as a genetic fusion followed by recombinant protein purification or as a synthetic peptide that is 
chemically linked to a suitable carrier. A very efficient and cost-effective way to make M2e immunogenic 
is generating recombinant virus-like particles that display M2e on their surface. Neirynck et al. 
genetically fused M2e to the hepatitis B virus core protein, which forms a virus-like particle with M2e 
radiating from the surface [32]. A variant of this is to use lipid enveloped VLPs in which M2e is 
embedded by its natural or a heterologous membrane anchor. For example, tandem repeats of M2e fused 
to the transmembrane domain of hemagglutinin were efficiently incorporated into VLPs and induced 
broad protection against influenza A virus challenge [69]. Many types of VLPs have been used to  
display M2e and to evaluate their efficacy as vaccines. Ease and economy of expression and purification 
may vary significantly, and successful approaches include the use of Malva mosaic virus (MaMV) 
nanoparticles [70], tobacco mosaic virus coat protein [71], potato virus X [72], Alternanthera mosaic 
virus coat protein [72], papaya mosaic virus [73], human papillomavirus [74], and woodchuck hepatitis 
virus-like particle [75]. Bacteriophage-based M2e-displaying vaccines have also been developed, which 
have the notable advantage that these are very easy to grow and scale up. Bacteriophages T7 and Qβ 
have been used to display M2e [76,77]. 
Efforts have also been made to present M2e as a soluble tetrameric antigen. We used a strategy based 
on a tetramerizing leucine zipper derived from GCN4 (General Control Non-derepressable 4). The 
resulting M2e-tGCN4 elicited protective immunity and, based on a competition ELISA, we obtained 
evidence that this approach induced tetrameric M2e-specific antibody responses in immunized BALB/c 
mice [78]. M2e genetically fused to a coiled-coil forming part of non-structural protein 4 of rotavirus 
also resulted in tetramer formation in solution and protected BALB/c mice from 3 LD50 PR8 challenge [79]. 
Synthetic M2e peptides are very soluble and can be chemically linked to different carriers. For 
example, scientists from the Wistar have developed the synthetic M2e-multiple antigen peptide (MAP) 
constructs by linking full length or truncated M2e2-16 and different Th-determinants to a lysine-rich 
synthetic carrier and showed M2e-based immune protection [56,80–83]. Other examples of chemical 
conjugates between M2e and carriers include the use of bovine serum albumin (BSA), KLH and 
Neisseria meningitidis outer membrane protein complex (OMPC), all of which are able to induce  
M2e-specific protective humoral immunity [66,84–86]. 
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Like most other subunit vaccine antigens, immunogenicity of M2e-fusion constructs is strongly 
enhanced by an adjuvant. Different approaches have been followed to fuse M2e with an adjuvant.  
In collaboration with the group of Nils Lycke, we took advantage of the safe and potent mucosal adjuvant 
CTA1-DD, which is derived from Cholera toxin but lacks the pentameric B domain of this toxin. As such 
we generated CTA1-3M2e-DD and showed that this recombinant protein induced robust M2e-specific 
IgG, IgA as well as M2e-specific CD4 T cell responses after mucosal immunization [64]. The company 
VaxInnate developed M2e-flagelin [87–89] and Merck evaluated M2e fused to OMPC [85,86]. Other 
proteins endowed with adjuvant activity that have been used as carriers for M2e include Brucella 
lumazine synthase decameric carrier [90] and recombinant nanorings composed of the human Respiratory 
Syncytial virus (HRSV) nucleoprotein, containing bacterial RNA fragment [91]. Interestingly, immunization 
with the latter construct protected against both influenza and HRSV challenge in a mouse model. 
DNA vaccines remain attractive because they are cheap, easy to design and physically stable. In fact, 
the only marketed DNA vaccine is for prophylaxtic use in the veterinary field [92]. M2(e) has been 
included in different DNA vaccine formats to try to induce broad immune protection against influenza 
A, usually alone or as one of several components, i.e., next to HA and/or NP antigens [93–97]. In general, 
when M2 was used as a gene vaccine, M2e-specific antibody responses were very low. A caveat of full 
length M2 expression by genetic vaccine approaches is that the cells that express M2 from a gene vector 
in vivo are likely to die because of the ion channel activity.  
Live vectors have been successfully used to induce immune responses against a diverse set of 
heterologous microbial pathogens in experimental settings. One attractive advantage of live vectors is 
their capacity to induce strong T cell responses. However, as mentioned above, immune protection by 
M2e-based vaccines relies primarily on M2e-specific antibodies. Several groups have explored live 
vectors to induce M2-specific immune responses. In many cases, full length M2 was expressed and 
delivered by the vector. This strategy induces very low humoral anti-M2e responses, reminiscent of the 
natural response to M2e. Furthermore, it is likely that antigen-presenting cells that become infected with 
the recombinant virus that delivers M2, will die because of the viroporin activity of M2 [98]. Still, a 
number of groups succeeded in showing immune protection by M2(e)-based vaccination approaches  
that relied on live vector delivery. Zhou et al. developed the recombinant chimpanzee-derived 
replication-defective adenovirus (AdC) vectors, AdC68, that was modified to express M2e within 
variable regions 1 or 4 of the Adenoviral hexon [99]. Two intramuscular doses of this vector induced 
strong humoral immunity in mice against a 10 LD50 PR8 challenge [99]. Another replication-incompetent 
human adenovirus-vectored influenza vaccine was engineered to express both H5 HA and four tandem 
copies of M2e. Intranasal administration of this adenoviral vaccine provided heterosubtypic immunity 
(HSI) in BALB/c mice that lasted up to twelve months [100]. Layton et al. introduced M2e6-13 
(EVETPIRN) combined with a potential immune enhancing epitope into the genome of a recombinant 
attenuated Salmonella enteritidis strain [101]. This live bacterium was used to immunize Leghorns 
chicks by oral gavage. Interestingly, the vaccination resulted in M2e-specific serum IgY responses and 
protected the chicks against challenge with H7N2 virus but not against H5N1 virus challenge [101]. The 
Baxter Bioscience group reported on the use of Modified Vaccinia Ankara (MVA) to express NP, M1, 
M2, PB2, the stem region of HA (hlHA) and the stem region of HA with a tandem repeat of four M2e 
sequences (hlHA/M2e). Immunization of BALB/c mice with MVA-M2, MVA-hlHA or MVA-hlHA/M2e 
provided comparable and very modest protection against challenge with H5N1, H9N2 or H7N1 viruses. 
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Only vaccination with NP-expressing MVA vectors did provide protection against challenge with these 
viruses [102]. 
Laboratory mice are widely used to demonstrate immune protection by new experimental vaccine 
approaches. The mouse is an important and relevant animal model for influenza because it allows 
obtaining proof of concept findings of new approaches and, more importantly, allows studying the 
mechanism of action of the experimental vaccine at hand. This can lead to surprising findings. For 
example, many groups have shown that broadly protective IgG antibodies that target the conserved 
influenza HA stalk, have in vitro virus-neutralizing activity. However, when it comes to in vivo 
protection, these antibodies rely heavily on antibody-dependent cytotoxic or phagocytic mechanisms as 
was demonstrated using Fcγ Receptor-deficient mice [103,104]. However, there are a number of caveats 
associated with the mouse model for influenza. First, mice are not natural hosts for influenza viruses. 
Secondly, most researchers use lethal challenge models of influenza in mice to make conclusions on 
immune protection or protection by antivirals. Human influenza is rarely a lethal disease. Finally, most 
mouse studies are done in inbred animals that are often also immunologically naïve to influenza. This 
contrasts with the genetic diversity in the human population and the pre-existing B and T cell memory 
against influenza viruses that many people carry. 
Ferrets, pigs, horses, and chickens are natural hosts for influenza. In addition, non-human primates 
such as macaques are increasingly used for influenza virus challenge and pathology experiments.  
Like humans, macaques exhibit clinical symptoms, such as fever, malaise, nasal discharge, and 
nonproductive cough, after influenza virus infection. Moreover, the virus load can be detected in the 
nasal cavity and respiratory tract [105,106]. Immune protection studies in at least one of these species 
are essential before clinical studies can be initiated with novel influenza vaccine candidates. So, how 
well do M2e-based vaccines protect against influenza in speices other than mice?  
M2e chemically conjugated to KLH or OMPC was very immunogenic in BALB/c mice, ferrets, and 
rhesus monkeys [85]. In a direct comparison of M2e-HBc with M2e-OMPC, the Merck group reported 
that both experimental vaccines were highly immunogenic in mice but, surprisingly, M2e-OMPC was 
much more immunogenic in rhesus macaques than M2e-HBc [86]. 
Ferrets are attractive laboratory mammalian models for studying the pathology and transmission of 
human influenza viruses. The respiratory tract of the ferret resembles that of the human with regard to 
lung physiological characteristics and the distribution of influenza virus receptors [107,108]. Immunization 
of ferrets with M2e-KLH or M2e-OMPC efficiently elicited M2e-specific antibodies and significantly 
reduced viral shedding in challenged ferrets’ lungs [85]. Pigs can be infected with swine, human, and 
avian viruses because they express both avian and human influenza A preferred binding receptors:  
N-acetylneuraminic acid-α2, 3-galactose (NeuAcα2,3Gal) and NeuAcα2,6Gal linked sialyloligosaccharides, 
respectively [109]. Pigs are therefore considered an important natural mixing vessel for influenza A 
viruses [110]. Intradermal administration of DNA vaccine encoding M2e fused to NP induced  
M2e-specific serum IgG in pigs but antibody levels were much higher in animals that had been 
vaccinated with M2e-HBc VLPs in the presence of an adjuvant. Following challenge with a swine H1N1 
virus expressing M2e that differed at six positions compared to the human M2e-HBc VLP antigen [32], 
all animals had increased body temperature that peaked on Day 1−2 after challenge. Remarkably, pigs 
that had been vaccinated with the M2e-NP genetic vaccine developed exacerbated disease following 
challenge, possibly due to an overt or derailed T cell response. Interestingly, the pigs with the highest 
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antibody titers against M2e (i.e., those immunized with M2e-HBc VLP in the presence of an adjuvant) 
quickly controlled the fever, suggesting a level of clinical protection [111]. Chickens are another 
economically important species and moreover occasionally transmit low or highly pathogenic influenza 
A viruses to human. Orally administered Salmonella-vectored vaccine expressing M2e in combination 
with a potential immune-enhancing CD154 peptide protected chickens against intranasal challenge with 
106 50% embryo infectious dose per bird of H7N2, a low pathogenic avian influenza virus [101]. 
Intranasal administration of live Lactococcus lactis expressing M2e on the bacterial surface and 
subcutaneous injection of M2e-KLH prolonged the survival time of chickens after H5N2 highly 
pathogenic avian influenza virus challenge [112]. Finally, immunization of chickens with tandem copies 
of M2e fused with maltose binding protein (MBP) induced high M2e-specific antibody responses and 
protected against H5N1 challenge in chicken [113]. 
It is advantageous to combine M2e with other influenza A antigens. Combining HA and M2e is an 
attractive approach for the development of broad-spectrum influenza vaccines. Immunization with a 
recombinant Adenoviral (rAd) vector encoding H5 HA together with four tandem copies of M2e 
(rAdH5/M2e) induced superior cross-protection in BALB/c mice compared to those immunized with 
rAd encoding H5 HA or M2e alone. Of note, one intranasal dose of rAdH5/M2e induced a significantly 
higher level of M2e-specific antibodies and conferred more effective protection against heterologous 
H1N1 in BALB/c mice as compared to that induced by rAd encoding only M2e. This shows that 
rAdH5/M2e induces potent and long-lasting cross-protection [100]. A DNA vaccine encoding M2e 
together with H1 HA induced significantly higher HA-specific CD8+ and M2e-specific T cell responses 
than a DNA vaccine encoding M2e or H1 HA alone and provided complete protection against H5N2 
challenge in mice [95]. An overview of the above described M2e-based vaccines is provided in Table 1. 
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Table 1. Overview of M2e based vaccines.  
Overview of M2e Based Vaccines 
Vaccine 
Type 
Carriers 
Copy 
Numbers 
Antigen Type 
Immunogenicity Readout in Animal Models 
(Administration Routes) 
Reference 
VLPs 
HBc 1, 2, 3 human 
Mice (intranasal, intraperitoneal)  
Pigs (intramuscular), Human 
[32,111,114–116] 
HA(TM) 5 human, swine, avian Mice (intramuscular) [69] 
MaMV 3 canine mice (subcutaneous), dogs (intramuscular) [70] 
Tobacco mosaic virus coat protein 1 human Mice [71] 
Papaya mosaic virus 1 human Mice (subcutaneous) [73] 
Woodchuck hepatitis VLP vectored 
in Salmonella Typhimurium 
1 avian-like Mice (oral) [75] 
T7 1 human Mice (subcutaneous) [76] 
Q-β 1 human Mice (intranasal, subcutaneous) [77] 
DNA 
Complete NP  1 swine Pigs (intradermal) [111] 
VP22, tegument protein  
of bovine herpesvirus-1 
1 human Mice (intramuscular) [93] 
HA, NP (147-155) 1 human Mice (gene gun) [94] 
HA 1,2 human, avian Mice (gene gun, intramuscular) [94,95] 
peptide 
- 1 human Mice (subcutaneous) [65] 
Multiple antigen peptide 1, 4 human, avian Mice (intranasal, subcutaneous) [56,80–83] 
  
Vaccines 2015, 3 118 
 
 
Table 1. Cont. 
Overview of M2e Based Vaccines 
Vaccine 
Type 
Carriers 
Copy 
Numbers 
Antigen Type 
Immunogenicity Readout in Animal Models 
(Administration Routes) 
Reference 
protein 
Influenza NP 8 - Mice [117] 
CTA1-DD 1, 3 human Mice (intranasal) [64] 
tGCN4 tetramer human Mice (intraperitoneal, intranasal) [78] 
rotavirus fragment NSP4 tetramer human Mice (subcutaneous) [79] 
KLH 1 human, avian 
Mice (subcutaneous, intramuscular),  
Ferrets (intramuscular), Rabbit 
[66,85] 
OMPC 1 human 
Ferrets (intramuscular),  
Rhesus Monkey (intramuscular) 
[85,86] 
RSV NP 1, 3 human Mice (intranasal, subcutaneous) [91] 
BLS 1, 4 human Mice (intranasal, subcutaneous, intramuscular) [90] 
glutathione S-transferase 1, 4, 8 human Rabbit (subcutaneous) [118] 
flagelin 4 human 
Human (intramuscular),  
Mice (subcutaneous, intranasal) 
[87] 
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6. Mechanisms of Protection by M2e-Based Vaccines: Universal Protection and Beyond 
Understanding the mechanism of protection by M2e-based vaccines is critical for future clinical trials. 
Since 1998, when Zebedee and Lamb reported that the M2e-specific mouse monoclonal antibody 14C2 
was able to restrict the in vitro replication of some strains of influenza A [119], nearly all publications 
on M2e-based immune protection have monitored M2e-specific antibodies and often demonstrated that 
IgG against M2e is essential for protection against influenza A virus challenge. This is consistent with 
studies showing that mice can be protected against influenza A virus challenge by injection of M2e-specific 
monoclonal antibodies [120–124] or M2e-vaccine derived immune serum [32,85,125,126]. This suggests 
that protection by M2e vaccination depends on antibodies, and it was speculated early on that this protection 
was mediated by antibody dependent NK cell activity rather than by direct virus neutralization [127]. The 
involvement of NK cells for immune protection by M2e-specific IgG was proposed based on NK cell 
depletion experiments where the mice were treated with anti-asialo-GM1 before lethal PR8 challenge. 
This experiment revealed that there was no protection in M2eHBc immunized mice that had been 
depleted of NK(T) cells [127]. However, other groups reported that NK cells were not involved in the 
protection by M2e vaccine, showing that mice depleted of NK cells using anti-NK1.1 or anti-asialo-GM1 
showed similar protection as control groups [126]. Instead, Fcγ Receptors expressed on alveolar 
macrophages were identified as crucial players in anti-M2e IgG mediated immune protection [128]. 
Wang et al. found that passive transfer of a human anti-M2e monoclonal antibody failed to protect C3 
knockout C57Bl/6 mice against influenza A virus challenge, implying that complement contributes to 
protection [129]. The types of M2e-specific IgG isotypes that are induced by immunization are somewhat 
predictive for the protective effectiveness in mice [26,65,130]. In general, IgG2a responses reflect a Th1 
type of immune response and, for viral infections, these isotype antibodies correlate better with 
protection than IgG1 does [131]. We found that significantly increased levels of IgG2a/IgG1 responses 
and improved protection against viral challenge were obtained when M2eHBc was adjuvanted with 
CTA1-DD, after both intranasal and intraperitoneal administration in BALB/c mice [132]. This 
difference correlates with the higher affinity of IgG2a antibodies for the activating receptors FcγRI, -III 
and -IV, whereas mouse IgG1 only binds significantly to FcγRIII [133]. Passive transfer of the IgG1 
fraction purified from polyclonal M2eHBc hyper immune mouse serum protected wild type but not 
FcγRIII−/− mice from challenge. When M2e-specific IgG2a was present, FcγRIII−/− mice were protected 
against challenge, suggesting compensatory interactions between IgG2a and (an)other Fc receptor(s), 
like FcγRIV, in these knockout mice [128]. 
Given the importance of Fcγ Receptors for M2e-based immunity in mice, it is somewhat puzzling 
that immunization with M2e conjugates also works in chickens. In birds the predominant circulating 
antibody is IgY, which is considered an ancestral form of mammalian IgE and IgG and is functionally 
most similar to IgG. IgY is recognized by the high-affinity FcY receptor (chicken lg-like receptor 
(CHIR)-AB1), a member of the leukocyte receptor family. CHIR-AB1 binds IgY in a similar way as 
human FcαRI binds IgA. The IgY receptor is expressed on chicken B cells, macrophages, monocytes 
and NK cells [134,135]. A truncated form of IgY that lacks an Fc tail, IgY(ΔFc), is present in ducks and 
appears to be a structural equivalent to F(ab')2 fragment of mammalian IgG [136]. Extrapolating the 
findings on the protective mechanism of M2e-based immunity from mice to birds would mean that only 
full length IgY contributes to protection. 
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Taken together, antibody dependent cell-mediated cytotoxicity (ADCC), complement dependent 
cytotoxicity (CDC) and antibody dependent cell-mediated phagocytosis (ADCP) are the main mechanisms 
of anti-M2e IgG protective immunity. The murine FcγR family consists of four activating receptors, 
FcγRI, FcγRII, FcγRIII and FcγRIV. The contribution of FcγRIV in immune protection by anti-M2e IgG 
remains unclear and it will be interesting to address this question in the future, by studying protection 
using FcγRIV-deficient mice. 
Based on a large set of passive transfer experiments in laboratory mice, it seems fair to conclude that 
antibodies directed against M2e are essential for immune protection by M2e-vaccines. A number of 
groups therefore explored the use of anti-M2e IgG immunotherapy to prevent or treat disease caused by 
influenza A virus infections. Fu et al. generated four anti-M2e antibody hybridomas using standard 
protocols for monoclonal antibody production. Epitopes were mapped in ELISA using a series of 
truncated M2e peptides. This showed that the antibodies recognizing the highly conserved N-terminal 
sequence of M2e provided better protection in mice [124]. Human monoclonal antibodies directed 
against the N-terminus of M2e have been isolated from a healthy individual by screening IgG+ memory 
B cells isolated from PBMC of M2e-seropositive subjects. Among these isolated antibodies, TCN-031 
and TCN-032 efficiently bind to tetrameric M2 on virions or PR8-infected cells and have a low affinity 
for synthetic M2e peptides. In addition, these human monoclonal antibodies protected mice against 
challenge with highly pathogenic H5N1 virus [123]. Theraclone, the company who developed these 
human monoclonal antibodies, went a step further and evaluated TCN-032 in a phase I clinical study. 
This study revealed that parenteral administration of this M2e-specific IgG monoclonal antibody was 
very well tolerated. More recently, 40 healthy adult volunteers were enrolled for a phase II study to 
evaluate clinical protection against experimental influenza A virus challenge. This drug study showed 
that daily influenza symptom scores (1–7 days) were significantly reduced in TCN-032 treated subjects 
compared to placebo subjects. In addition, the median viral load in the TCN-032 treated and challenged 
volunteers was more than two logs lower compared to the placebo treated group [137]. No difference in 
time to peak symptoms (at Day 3) was reported, which is consistent with the M2e antibody mechanism 
requiring recruitment of effector immune cells to mediate infected cell clearance. This first study in 
humans with an M2e-based antibody therapy should be considered as an important landmark for further 
clinical development of active and other passive M2e-directed immunization strategies. 
Song et al. generated a fully human M2e-specific monoclonal antibody (Z3G1). The prophylactic and 
therapeutic administration of Z3G1 resulted in significant protection of mice and alleviated clinical 
symptoms and reduced lung pathology following pandemic H1N1 infection of monkeys. A derivative 
of Z3G1, called AccretaMab® Z3G1, was generated that had a chimeric IgG1/IgG3 Fc region and was 
de-fucosylated. This modification resulted in increased ADCC and CDC activities in vitro using PBMC 
from different human donors [138]. 
In contrast to neutralizing antibodies elicited by seasonal influenza vaccines, M2e-specific antibodies 
will initiate viral clearance by binding to infected cells, implying that at least a first round of infection 
must take place before anti-M2e antibodies can exert their protective effect. An undeniable advantage 
of infection-permissive M2e vaccine over HA-matching conventional vaccine is that they allow the 
induction of CD8 T cell immunity. Evidently, at higher challenge doses, protection of mice after 
immunization with M2-HBc may therefore be less potent than that achieved with UV-inactivated  
HA-matched influenza A vaccines. Nevertheless, we have reported that body weight loss is completely 
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absent in M2e-VLP immunized mice that were challenged with a dose of pandemic 2009 influenza A 
virus that induced severe weight loss in control mice or in mice that had been vaccinated with a 
mismatched whole inactivated influenza vaccine [139]. Although it is unclear if annual influenza 
vaccination of people is associated with reduction of cross-reactive CD8+ T cell responses, there is a 
possibility that such a response could be reduced in the long term if one starts to vaccinate children from 
a very early age onwards [140]. Notably, influenza vaccination of people from the age of 6 months 
onwards is recommended in the US [141]. It has been proposed and shown in experimental vaccination 
and challenge experiments in mice and ferrets, that immunization with conventional vaccines can offer 
full protection against a homologous challenge and, on the downside, suppresses the induction of CD8 
T cell responses directed against the conserved internal viral proteins, some of which are highly 
conserved and have been shown to contribute to protection against heterosubtypic viruses [142–144]. 
Moreover, there is some evidence that influenza vaccination of children also affects their T cell responses 
against H5N1 virus [145]. We showed that, in the mouse model, M2e-based immune protection was not 
only protective against different influenza A virus strains, but also that CD8 T cells directed against the 
conserved nucleoprotein of influenza A were induced in the M2e-immune animals following primary 
infection. Together with the M2e-specific antibodies, these CD8 T cells protected against challenge with 
a secondary, heterosubtypic virus [139]. 
The degree of M2e epitope density on the carrier molecule is a critical factor for the induction of a 
strong M2e-specific immune response [114,118,146]. Multiple tandem copies of M2e in a vaccine 
construct could elicit higher M2e IgG titers than one copy M2e containing construct. We constructed 
M2eHBc particles with one (1604), two (1817) or three (1818) M2e copies fused to the N-terminus of 
HBc subunits. We found that vaccination with 1817 or 1818 constructs induced higher M2e-specific IgG 
titers and protection than 1604 [115]. Likewise, an MBP-3-M2e vaccine candidate conferred better 
protection than a one M2e copy containing construct against H5N1 infection in chicken [113]. To induce 
more universal protection against influenza A virus infection, it is advised that the M2e antigen in 
influenza vaccine contains M2e variants with PI-PT-LT type M2e sequences (Figure 1B). The important 
role of the proline residue at position 10 in M2 for recognition by some early described mouse 
monoclonal antibodies was demonstrated in an escape selection experiment by the group of Walter 
Gerhard. Chronic treatment of PR8 virus infected SCID mice with anti-M2e mouse monoclonal 
antibodies delayed disease progression. However, eventually M2e-escape mutants broke through in the 
anti-M2e IgG treated SCID mice. Only viruses with P10L and P10H substitutions in M2(e) were  
isolated [121]. Of note, these two replacements are usually found among the highly pathogenic avian 
influenza H5 and H7 viruses. The M2e-specific IgG2a monoclonal antibodies that were used for 
treatment failed to bind to M2 from the P10L or P10H on the surface of MDCK cells that had been 
infected with the escape viruses [121]. However, no escape mutants emerged after 11 consecutive 
passages of PR8 in BALB/c mice that had been actively vaccinated with M2e. These unpublished data 
indicate that M2e, though not completely invariant, is still stable under strong immune pressures. 
Intranasal immunization is a preferred and logical route to control disease caused by respiratory 
pathogens such as influenza viruses. Not surprisingly, intranasal/mucosal immunization has often been 
explored for M2e based vaccines. In addition, administration of a needle-free vaccine can offer a logistic 
advantage in case of a pandemic outbreak, when time and trained medical personnel could be limiting. 
Using a highly immunogenic nanoparticle based on recombinant nucleoprotein of respiratory syncytial 
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virus substituted with three tandem copies of M2e, Herve et al. compared the effectiveness of intranasal 
and subcutaneous vaccination in BALB/c mice. Anti-M2e IgG1 and IgG2a titers were comparable in 
both groups but only intranasal immunization gave rise to anti-M2e IgA responses. These IgA antibodies 
were present in serum and locally in the bronchoalveolar lavage fluid. Intranasally immunized mice were 
better protected than subcutaneously immunized mice against challenge with PR8 virus [91]. This 
finding is in agreement with previous findings [32,56,77,81,132]. The local anti-M2e IgA induction also 
played a critical role in protection, but the mechanism of anti-M2e IgA mediated protection remains 
unclear. However, intranasal influenza vaccines for human use suffered a setback due to reported severe 
side effects related to the used adjuvant [147]. 
7. Clinical Development of M2e-Based Vaccines  
A few Biotech companies have evaluated M2e-containing vaccines in early phase clinical trials. The 
prime purpose of phase I clinical studies is to document safety and, in case of vaccines, immunogenicity. 
Since M2e is naturally poorly immunogenic, it was important to demonstrate that M2e-vaccines could 
induce strong M2e-specific antibody and potentially T cell responses. Ideally, such responses should be 
long lasting. VaxInnate reported on their phase I clinical trial with different doses of VAX102, a 
recombinant flagellin protein (a TLR5 ligand) with four tandem copies of M2e fused at the C-terminus. 
Doses of 0.3 and 1.0 μg VAX102 injected intramuscularly were safe and induced up to one 1 μg/mL of 
anti-M2e IgG in circulation. Higher doses of VAX102 were however associated with severe symptoms [87]. 
Researchers from Dynavax constructed a recombinant protein antigen, comprising eight copies of 
M2e fused to NP. This protein was covalently linked to an immunostimulatory sequence (ISS) that is 
owned by Dynavax and is a ligand for Toll like Receptor 9, creating N8295. N8295 was successfully 
evaluated in two phase 1 studies in healthy volunteers, as a standalone antigen and combined with a 
poorly immunogenic dose of an H5N1 vaccine. N8295 induced M2e- and NP-specific antibodies as well 
as NP-specific cellular responses. In addition, no serious adverse events were reported and adding N8295 
to the H5N1 vaccine augmented HA-specific antibody responses to that vaccine [117].  
In a randomized, double-blind, placebo-controlled phase I clinical trial of M2eHBc (ACAM-FLU-A™) 
sponsored by Acambis (later acquired by Sanofi Pasteur), the intramuscularly injected ACAM-FLU-A™ 
was well tolerated and able to generate anti-M2e seroconversion in up to 90% of healthy  
volunteers [116,148]. However, further clinical development of this M2e vaccine candidate as a 
standalone vaccine is unlikely, in part because the M2e-specific antibody titers dropped fairly rapidly 
over time. 
A DNA vaccine that comprises an M2 expression plasmid in one of the arms was also conducted. 
The prime purpose of this study was to show that the use of the proprietary Vaxfectin adjuvant could 
improve immune responses induced by DNA vaccination in humans. The clinical study involved  
103 healthy adults who received two injection of Vaxfectin adjuvanted monovalent DNA (encoding H5 HA) 
or trivalent DNA vaccine with plasmids encoding HA, NP and M2. M2e-specific total IgG antibody 
responses were observed only at the highest DNA dose and in approximately one third of the subjects [149]. 
As mentioned earlier, DNA vaccination with full length M2 is suboptimal to induce M2e-specific 
immune responses. 
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8. Conclusions and Future Perspectives 
Influenza vaccine is regarded as the first prophylactic line to protect people from disease caused by 
influenza viruses. Influenza vaccines are very safe and usually effective, however, these conventional 
influenza vaccines need to be updated almost every year to anticipate circulating flu viruses that 
antigenically deviate from those that were prevalent in former seasons. As yet, there is no licensed 
broadly protective influenza vaccine that could be implemented right after the start of a new pandemic. 
Such a universal influenza vaccine could also be used to prevent seasonal influenza, provided that it 
proves to be non-inferior to the existing seasonal influenza vaccines that mainly rely on the induction of 
strain-specific virus neutralizing antibodies. In other words the bar is high for competing technologies. 
M2 is a viroporin that plays an important role during the early stages of virus entry. In addition, recent 
discoveries have attributed immune-modulatory roles to M2 since it disturbs and exploits autophagy and 
can activate the inflammasome. Remarkably, the natural immune response against M2, and in particular 
against M2e, is very modest, most likely due to its low abundance on virions. 
M2e is a highly conserved target for universal influenza A vaccine development. Different types of 
M2e-based vaccine, such as DNA vaccine, protein vaccine, VLPs vaccine, and vectored vaccine, are all 
able to provide a certain level of broad-spectrum protection in animal models. The influenza A virus 
infection cycle and possible mechanisms of M2e-based vaccine-mediated protection are summarized in 
Figure 3. M2e-specific antibodies, mainly IgG, are the main actors in immune protection and do so by 
engaging Fcγ Receptor expressing immune cells such as alveolar macrophages. It is also well 
documented that mucosal immunization with M2e-based vaccines offers better protection in mouse 
models compared to parenteral immunization strategies. This improved protection may be attributable 
to the induction of M2e-specific IgA. The infection-permissive character of M2e-based vaccines can be 
considered as an advantage when vaccinating immunologically naïve individuals. Because M2e-immunity 
does not neutralize the virus, the limited virus replication still induces cross-reactive T cell responses 
against other conserved viral antigens such as NP and M1. However, M2e will likely not be a complete 
substitute for the currently licensed influenza vaccines that are able to confer much stronger protection, 
be it against a very narrow antigenic range of viruses. In the future, with many other universal influenza 
vaccine candidates on the horizon, M2e-conjugate vaccines will likely find a place as part of a vaccine 
that is a blend of different conserved epitopes that together may offer strong, long lasting, and foremost 
broad immune protection. Whether such a vaccine will perform better clinically than a fully antigenic 
matched seasonal vaccine remains to be seen. However, such universal vaccines would prove their value 
in the case of a pandemic. 
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Figure 3. Influenza A virus infection cycle and mode of action of M2e based vaccines.  
The influenza A virions bind to sialic acid containing receptors on the surface of cells. 
Following endocytosis, the acidification of the endosome triggers the low-pH activation of 
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M2. Then, the viral membrane fuses with the endosomal membrane by a low pH induced 
conformational change in HA. The interaction between M1 and vRNPs loosens after H+ 
influx by activated M2 ion channels, resulting in the release of vRNPs into the cytosol.  
In the nucleus, cRNA(+), vRNA(−) and mRNA(+) are produced, allowing the influenza A 
virus genome and proteins synthesis. Most likely M2 mediates the lipid recruitment from 
autophagosome during virus budding. The influenza A virus components and vRNP are 
packaged at the membrane, allowing the release of newly produced virions from the apical 
side of airway epithelial cells and the virus spreads. The critical steps in virus replication 
cycle and the M2(e) vaccine mechanism of action are highlighted in bold and in red.  
M2e-derived epitopes are presented in the context of MHC II molecules. M2e-specific CD4+ 
T cells are activated via T cell receptors recognition of these presented M2e epitopes, and 
release cytokine and chemokine in order to offer bystander help to antibody producing 
plasma cells or possibly clear infected cells as Cytotoxic CD4+ T lymphocytes. Phagocytes 
can recognize M2e-specific IgG immune complexes on the surface of infected cells and 
subsequently kill and eliminate the infected cell. Recognition of M2 on the surface of infected 
cells by phagocytic cells depends on Fc receptors and opsonizing anti-M2e IgG antibodies.  
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